Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.63 |
| ▸ | KHK | P50053 | 3/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28794168 | 0.83 | KHK (0.46) | ADRB1KHKMAPTALDH1A1 | |
| SCHEMBL2245201 | 0.83 | HTR3E (0.61) | ADRB1KHKNOTUMMAPTALOX5 | |
| SCHEMBL12892626 | 0.83 | HTR3E (0.61) | ADRB1KHKNOTUMMAPTALOX5 | |
| SCHEMBL8109027 | 0.83 | KHK (0.50) | ADRB1KHKMAPT | |
| SCHEMBL4240000 | 0.83 | HTR3E (0.61) | ADRB1KHKNOTUMMAPTALOX5 | |
| SCHEMBL30208090 | 0.83 | HTR3E (0.61) | ADRB1KHKNOTUMMAPTALOX5 | |
| SCHEMBL23711775 | 0.82 | KHK (0.55) | ADRB1KHKMAPTALDH1A1RAB9A | |
| SCHEMBL31279241 | 0.82 | KHK (0.55) | ADRB1KHKMAPTALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL20139242 | 0.81 | HTR3E (0.59) | ADRB1KHKNOTUMMAPTALOX5 | |
| SCHEMBL2873025 | 0.81 | ADRB1 (0.65) | ADRB1KHKMAPTKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | ADRB1 225/4885KHK 2803/4885NOTUM 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.